التفاصيل البيبلوغرافية
| العنوان: |
A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma. |
| المؤلفون: |
Gouda, Mohamed A., Stephen, Bettzy, Tian, Yanyan, Alshawa, Anas, Onwugaje, Dilichukwu O. Chudy, Albittar, Aya, Yali Yang, Zarifa, Abdulrazzak, Yilmaz, Bulent, Gurses, Serdar, Sprenger, Ashabari, Derbala, Mohamed H., Brink, Amanda, How, Jeffrey Andrew, Moyers, Justin, Piha-Paul, Sarina A., Hong, David S., Meric-Bernstam, Funda, Patel, Sapna P., Oliva, Isabella Glitza |
| المصدر: |
Journal of Immunotherapy & Precision Oncology; Nov2024, Vol. 7 Issue 4, p247-254, 8p |
| مصطلحات موضوعية: |
LEUKOCYTE count, IMMUNE checkpoint inhibitors, PLATELET count, MELANOMA, CELL death |
| مستخلص: |
Introduction: Immune checkpoint inhibitors (ICIs) have substantially advanced the treatment of patients with malignant melanoma. However, improving therapeutic efficacy requires identifying drug combinations that elicit durable responses without inducing intolerable toxicity. Within that context, selinexor emerges as a possible combination option that has been shown in preclinical studies to enhance the efficacy of ICI therapy. Methods: In this phase 1b study, we investigated selinexor in combination with pembrolizumab in 25 patients with advanced non-uveal melanoma. Patients received selinexor at a dosage of 60 mg taken orally twice weekly, and pembrolizumab intravenously at a dosage of 200 mg every 3 weeks. Results: Despite the high incidence of adverse events (96%), most treatment-related toxicities were manageable with supportive care and dose reductions. The most common adverse events of any grade were nausea (n = 20; 80%), decreased white blood cell count (n = 15; 60%), vomiting (n = 14; 56%), anemia (n = 12; 48%), fatigue (n = 12; 48%), and decreased platelet count (n = 12; 48%). The 10 patients with treatment naïve evaluable disease had an objective response rate (ORR) of 70% (n = 7, including three patients with complete response), which was significantly higher than that of the 14 patients with prior anti-programmed cell death protein 1 (anti-PD-1) therapy, whose ORR was 7% (n = 1; p = 0.002). Stable disease was observed in two patients (20%) with treatment-naïve disease and seven patients (50%) with prior anti-PD-1 therapy. Conclusion: Selinexor combined with pembrolizumab showed promising antitumor activity in patients with treatment-naïve metastatic melanoma. The toxicity profile of the combination was consistent with that reported for individual agents, with no additional safety concerns. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Immunotherapy & Precision Oncology is the property of Innovations Journals and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder